Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study

Background: Intracranial hemorrhage (ICH) is associated with high mortality and morbidity, especially in patients under anticoagulative treatment. Andexanet alfa (AA) is a modified recombinant form of human factor Xa (FXa) developed for reversal of FXa-inhibitors, e.g., in the event of ICH, but expe...

Descripción completa

Detalles Bibliográficos
Autores principales: Rauch, Sebastian, Müller, Hans-Peter, Dreyhaupt, Jens, Ludolph, Albert C., Kassubek, Jan, Althaus, Katharina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224862/
https://www.ncbi.nlm.nih.gov/pubmed/35743469
http://dx.doi.org/10.3390/jcm11123399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224862/
https://www.ncbi.nlm.nih.gov/pubmed/35743469
http://dx.doi.org/10.3390/jcm11123399

Ejemplares similares